UK Edition
AdvertiseSubmit Company
Pharma JournalEvidence-Based Pharmaceutical Intelligence
CELL & GENE THERAPY

Catalent

C

Catalent

Cell & Gene TherapySomerset, United States
Visit Website

About Catalent

Catalent is one of the world's largest contract development and manufacturing organisations, supplying drug substance, drug product, and biologics capabilities to pharmaceutical and biotechnology companies across more than 40 countries. Founded in 2007 following the spin-off of Cardinal Health's pharmaceutical technologies and services division, the company built its reputation on solving formulation and delivery challenges that its clients cannot address in-house.

Drug Delivery Technologies

Catalent's portfolio of proprietary drug delivery platforms is a primary reason manufacturers turn to the company at early development stages. Its Softgel and Optiform technologies serve both small-molecule and biologics formulations, while the OptiMelt and Zydis orally disintegrating tablet platforms address specific bioavailability and patient-compliance challenges. These platforms are applied across therapeutic areas including oncology, rare diseases, consumer health, and central nervous system indications.

Biologics & Gene Therapy Manufacturing

In recent years, Catalent significantly expanded its biologics manufacturing capacity through a series of acquisitions and facility investments, most notably its purchase of the Bloomington, Indiana biologics site and the acquisition of Paragon Bioservices, which brought substantial cell and gene therapy manufacturing capability. The Harmans, Maryland gene therapy facility became one of the largest commercial-scale viral vector manufacturing sites in North America. This expansion positioned Catalent as a significant partner for advanced therapy developers requiring specialist fill-finish, cell culture, and analytical services.

Catalent operates across the United States, Europe, and the Asia-Pacific region, with major sites in Somerset (New Jersey), Brussels, Swindon, and Sydney among others. The company was publicly traded on the New York Stock Exchange under the ticker CTLT before Novo Holdings announced its acquisition in 2024, subsequently transferring a number of its biologics manufacturing sites to Novo Nordisk as part of that transaction.

The company serves customers ranging from the world's leading pharmaceutical groups to emerging biotech companies seeking development-stage formulation support through to commercial-scale supply. Further information is available at catalent.com.

Similar Companies

More in Cell & Gene Therapy

C

CSL

CSL Limited is one of the world's largest biotechnology companies by market capitalisation, built on more than a century of plasma science and vaccine development. Founded in 1916 as the Commonwealth Serum Laboratories in Melbourne, Australia, the company has grown from a government research body into a global ASX- and ADR-listed biotherapeutics group operating across more than 100 countries. Plasma-Derived Therapies and Behring The company's flagship division, CSL Behring, is among the world's leading manufacturers of plasma-derived therapies, supplying immunoglobulins, albumin, coagulation factors, and specialty products to patients with rare and serious conditions including primary immune deficiencies, haemophilia, and hereditary angioedema. CSL Behring operates one of the largest plasma collection networks globally, with hundreds of donation centres across North America and Europe, underpinning a manufacturing supply chain that processes tens of millions of litres of plasma each year. Seqirus and Influenza Vaccine Leadership CSL's second major division, Seqirus, is one of the two largest influenza vaccine producers in the world. Operating high-containment manufacturing facilities in the United Kingdom, the United States, and Australia, Seqirus supplies seasonal and pandemic influenza vaccines to governments and healthcare systems globally, including longstanding contracts with national immunisation programmes. The division's cell-based and adjuvanted vaccine technologies are recognised by public health authorities as meaningful advances over traditional egg-based manufacturing. In 2022 CSL completed the acquisition of Vifor Pharma, a Swiss-headquartered specialist in iron deficiency, nephrology, and cardio-renal therapies, substantially expanding the group's product portfolio and its presence in hospital and renal care markets. CSL is headquartered in Melbourne, Australia, with major operational hubs in King of Prussia (Pennsylvania), Marburg (Germany), and Bern (Switzerland). The group invests heavily in research and development, with a pipeline spanning recombinant therapies, gene therapy, and next-generation plasma fractionation. CSL's scale, century-long heritage in biologics manufacturing, and vertically integrated plasma network position it as a critical supplier to healthcare systems managing rare, chronic, and infectious disease. Further information is available at csl.com.

View profile
A

Akron Biotech

Trusted by the cell and gene therapy sector since 2006, Akron Biotech supplies the ancillary materials that underpin advanced therapeutic manufacturing. Operating under the Akron Bio brand, the company occupies a specialised position in the biotech supply chain, providing the raw materials and contract services that research teams and commercial manufacturers depend on at every stage of development and scale-up. The product portfolio centres on three core categories: cytokines and growth factors, human plasma derived products, and media and media supplements. These materials are critical inputs for cell expansion, gene vector production, and the broader biomanufacturing workflows associated with advanced therapies. Alongside its catalogue offering, Akron Biotech runs dedicated manufacturing services covering proteins, media and buffers, and transfection and transduction reagents, giving clients a single source for both off-the-shelf supply and custom-manufactured components. Quality assurance is presented as a defining characteristic of the business. The company maintains regulatory support documentation and certificates for its materials, reflecting the compliance requirements of partners working in regulated therapeutic development environments. A knowledge centre comprising published posters, publications, and event resources further supports the scientific community using its products. Partnerships and collaborations form part of the company's stated commercial model, positioning Akron Biotech as an integrated supplier rather than a transactional vendor. Its leadership and newsroom functions suggest an active presence in the cell and gene therapy market rather than a passive catalogue role. Further information is available at akronbiotech.com.

View profile
B

Biogen

Biogen pioneered the neuroscience field as one of the world's oldest independent biotechnology companies, founded in 1978 by a group of distinguished scientists including Nobel laureate Walter Gilbert. Headquartered in Cambridge, Massachusetts, the company has spent nearly five decades focused almost exclusively on neurological and neurodegenerative diseases, a level of specialisation that sets it apart from diversified pharma peers. Neuroscience Focus and Key Therapy Areas Biogen's portfolio centres on multiple sclerosis, where it holds one of the broadest treatment ranges in the industry, spanning injectable, oral, and infusion therapies. The company also works in spinal muscular atrophy, Alzheimer's disease, Parkinson's disease, and rare neurological conditions. Its partnership with Eisai produced lecanemab (marketed as Leqembi), an Alzheimer's treatment that received traditional FDA approval in 2023, marking a significant moment in a field that had seen decades of clinical setbacks. Global Scale and Commercial Presence Listed on the Nasdaq under the ticker BIIB, Biogen operates across more than 30 countries, with commercial infrastructure spanning North America, Europe, and Asia Pacific. The company invests heavily in research and development as a proportion of revenue, consistent with its identity as a science-led organisation rather than a marketing-driven one. Its biosimilars division, built through a long-standing collaboration with Samsung Bioepis, gives Biogen a commercial presence in the cost-sensitive biologics market alongside its branded neurology pipeline. Biogen has also expanded into rare disease and neuropsychiatry, reflecting a strategic effort to broaden the neuroscience platform beyond multiple sclerosis as the MS market faces increasing genericisation. The company's gene therapy interests, including assets in-licensed and acquired over recent years, signal further ambition in treating diseases at the molecular level. For professionals in pharmaceutical, biotech, and medical research sectors, Biogen represents one of the most focused large-cap neuroscience organisations operating globally. Further information is available at biogen.com.

View profile
AdvertisementTeksyte LTD

List Your Company

Showcase your company to thousands of pharma professionals.

Submit Listing

Advertise With Us

Reach decision-makers in the pharmaceutical industry.

Learn More

We use cookies and analytics to understand how the site is used and to keep the service free. Choose Accept All to allow this, or Essential Only to use just the cookies we need to keep the site working. You can change your choice any time in our Cookie Policy